Lucy A. Godley

Northwestern Medicine
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (14)

Deleterious germline DDX41 variants are the leading cause of heritable predisposition to myelodysplastic neoplasia and acute myeloid leukemia (MDS/AML). Accurate classification of pathogenicity is crucial for managing patients and their families. The absence of specific guidelines, along with late-onset disease, incomplete penetrance, and founder variants, poses challenges in clinical and laboratory practice. We aggregated a synthetic cohort (ASC) of DDX41 germline and somatic variants from 35 studies, including 1796 cases among 53686 patients, plus an additional 832 cases from non-cohort publications. We aimed to leverage the DDX41 -ASC to develop and refine ACMG/AMP criteria on case enrichment (PS4 ), somatic associations ( PP4 ), and computational prediction ( PP3/BP4 ). Analysis confirmed that deleterious germline DDX41 variants are most common in MDS/AML. A quasi-case-control study with ancestry matching revealed overestimated odds ratios for variants in underrepresented groups. Exploiting germline–somatic associations, we developed a Bayesian multinomial model that updates the odds of pathogenicity based on the presence and number of somatic patterns. Comparison of prediction tools showed that AlphaMissense outperformed REVEL in sensitivity. These results were integrated into an online tool to facilitate the consistent application of criteria. Overall, this comprehensive analysis of DDX41 -ASC provides an evidence framework to inform the development of DDX41 -specific curation guidelines.

Year:

2026

Deleterious germline DDX41 variants are the leading cause of heritable predisposition to myelodysplastic syndrome and acute myeloid leukemia (MDS/AML). Accurate classification of pathogenicity is crucial for managing patients and their families. The absence of specific guidelines, along with late-onset disease, incomplete penetrance, and founder variants, poses challenges in clinical and laboratory practice. We aggregated a synthetic cohort (ASC) of DDX41 germline and somatic variants from 36 studies, including 1802 cases among 53795 patients, plus an additional 832 cases from non-cohort publications. We aimed to leverage the DDX41 -ASC to develop and refine ACMG/AMP criteria on case enrichment (PS4 ), somatic associations ( PP4 ), and computational prediction ( PP3/BP4 ). Analysis confirmed that deleterious germline DDX41 variants are most common in MDS/AML. A quasi-case-control study with ancestry matching revealed overestimated odds ratios for variants in underrepresented groups. Exploiting germline–somatic associations, we developed a Bayesian multinomial model that updates the odds of pathogenicity based on the presence and number of somatic patterns. Comparison of prediction tools showed that AlphaMissense outperformed REVEL in sensitivity. These results were integrated into an online tool to facilitate the consistent application of criteria. Overall, this comprehensive analysis of DDX41 -ASC provides an evidence framework to inform the development of DDX41 -specific curation guidelines.

Year:

2025

Causal germline genetic variants are frequently detected in young (under age 40) patients presenting with myelodysplastic syndromes (MDS) or bone marrow failure (BMF), where progression to acute myeloid leukemia (AML) contributes substantially to mortality in these patients. We reasoned that de novo pediatric AML, which shares clinical and biological characteristics, might also share germline genetic risk variants. We investigated germline variants in a large cohort (n=365) of pediatric AML patients with whole-genome sequencing (WGS), 29 with matched marrow-derived stromal cells, and 336 with matched remission marrow samples. Variants were deemed “likely germline” based on variant allele frequency (VAF) across available samples. Following American College of Medical Genetics and Genomics (ACMG) and Association of Molecular Pathology (AMP) guidelines, we annotated pathogenic/likely pathogenic (P/LP) variants in 555 genes linked to leukemia risk. P/LP variants were identified in 5.5% (95% CI: (3.3%,7.9%)) of patients in genes linked to familial myeloid malignancy and an additional 3.3% (95% CI: (1.6%,5.2%)) of patients in genes conferring risk to lymphoid malignancy or solid tumors. The large cohort enabled burden testing, which we employed by comparing loss-of-function variants between patients and 2504 control subjects from the 1000 Genomes Project. There was a 6.9-fold (95% CI: (3.1,14.9)) increase in loss-of-function variants in genes implicated in myeloid malignancy risk, a 2.4-fold (95% CI: (1.7,3.2)) increase in candidate risk genes, and a 1.6-fold (95% CI: (1.1,2.3)) increase in randomly-selected genes. We then assembled cohorts totaling 4,622 pediatric and adult patients with acute leukemia or MDS from 10 published studies, and compared P/LP variant burdens across age and diagnosis. The prevalence of germline variants in myeloid malignancies across age groups exceeds 5% consistently and with high confidence. Because the National Comprehensive Cancer Network recommends that all patients receive screening if their pre-test germline variant probability exceeds 5%, our results support germline genetic variant testing as an integral component of diagnostic work-up for myeloid malignancies, including donor selection for stem cell transplantation.

Year:

2025

Somatic variants accumulate in all organs with age, with a positive selection of clonal populations that provide a fitness advantage during times of heightened cellular stress leading to clonal expansion. Easily measured within the hematopoietic compartment, clonal hematopoiesis (CH) is now recognized as a common process in which hematopoietic clones with somatic variants associated with hematopoietic neoplasms exist within the blood or bone marrow of individuals without evidence of malignancy. Most cases of CH involve a limited number of genes, most commonly DNMT3A, TET2, and ASXL1. CH confers risk for solid and hematopoietic malignancies as well as cardiovascular and numerous inflammatory diseases and offers opportunities for cancer prevention. Here, we explore the genetic and environmental factors that predispose individuals to CH with unique variant signatures and discuss how CH drives cancer progression with the goals of improving individual cancer risk stratification, identifying key intervention opportunities, and understanding how CH impacts therapeutic strategies and outcomes.

Year:

2024

Children harboring certain germline gene variants have an increased risk of developing myelodysplastic syndrome (MDS) and other hematopoietic malignancies (HM), such as leukemias and lymphomas. Recent studies have identified an expanding number of these predisposition genes, with variants most prevalent in children with MDS but also found in children with other HM. For some hematopoietic malignancy predispositions (HMP), specifically those with a high risk of MDS, early intervention through hematopoietic stem cell transplantation can favorably impact overall survival, providing a rationale for rigorous surveillance. A multidisciplinary panel of experts at the 2023 AACR Childhood Cancer Predisposition Workshop reviewed the latest advances in the field and updated prior 2017 surveillance recommendations for children with HMP. In addition to general guidance for all children with HMP, which includes annual physical examination, education about the signs and symptoms of HM, consultation with experienced providers, and early assessment by a hematopoietic stem cell transplantation specialist, the panel provided specific recommendations for individuals with a higher risk of MDS based on the affected gene. These recommendations include periodic and comprehensive surveillance for individuals with those syndromes associated with higher risk of MDS, including serial bone marrow examinations to monitor for morphologic changes and deep sequencing for somatic changes in genes associated with HM progression. This approach enables close monitoring of disease evolution based on the individual’s genetic profile. As more HMP-related genes are discovered and the disorders’ natural histories are better defined, these personalized recommendations will serve as a foundation for future guidelines in managing these conditions.

Year:

2024

Oncogenic mutations in isocitrate dehydrogenase (IDH)-1 and -2 occur in a wide range of cancers, including acute myeloid leukemia (AML) and glioma. Mutant IDH enzymes convert 2-oxoglutarate (2OG) to (R)-2-hydroxyglutarate ((R)-2HG)), an oncometabolite that is hypothesized to promote cellular transformation by dysregulating 2OG-dependent enzymes. The only (R)-2HG target that has been convincingly shown to contribute to transformation by mutant IDH is the myeloid tumor suppressor TET2. However, there is ample evidence to suggest that (R)-2HG has other functionally relevant targets in IDH-mutant cancers. Here, we show that (R)-2HG inhibits KDM5 histone lysine demethylases and that this inhibition contributes to cellular transformation in IDH-mutant AML and IDH-mutant glioma. These studies provide the first evidence of a functional link between dysregulation of histone lysine methylation and transformation in IDH-mutant cancers.

Year:

2024

Although numerous barriers for clinical germline cancer predisposition testing exist, the increasing recognition of deleterious germline DNA variants contributing to myeloid malignancy risk is yielding steady improvements in referrals for testing and testing availability. Many germline predisposition alleles are common in populations, and the increasing number of recognized disorders makes inherited myeloid malignancy risk an entity worthy of consideration for all patients regardless of age at diagnosis. Germline testing is facilitated by obtaining DNA from cultured skin fibroblasts or hair bulbs, and cascade testing is easily performed via buccal swab, saliva, or blood. Increasingly as diagnostic criteria and clinical management guidelines include germline myeloid malignancy predisposition, insurance companies recognize the value of testing and provide coverage. Once an individual is recognized to have a deleterious germline variant that confers risk for myeloid malignancies, a personalized cancer surveillance plan can be developed that incorporates screening for other cancer risk outside of the hematopoietic system and/or other organ pathology. The future may also include monitoring the development of clonal hematopoiesis, which is common for many of these cancer risk disorders and/or inclusion of strategies to delay or prevent progression to overt myeloid malignancy. As research continues to identify new myeloid predisposition disorders, we may soon recommend testing for these conditions for all patients diagnosed with a myeloid predisposition condition.

Year:

2024

Supplemental Table 1. List of DNA gene mutations tested in diagnostic tumor samples of our ALL cohort. Supplemental Table 2. List of 80 genes with RNA sequencing coverage. Supplemental Table 3. Demographics of 400 adult ALL cases. Supplemental Table 4. List of first-line (initial) therapies in Ph-positive B-ALL, Ph-negative B-ALL, and Tlineage ALL patients. Supplemental Table 5. Baseline gene rearrangements and structural variants of 329 molecularly characterized adult B-ALL patients. Supplemental Table 6. Baseline gene rearrangements and structural variants of 71 molecularly characterized adult T-lineage ALL patients. Supplemental Table 7. List of pathogenic/likely pathogenic germline variants in our ALL cohort. Supplementary Table 8. Multivariable analysis of overall survival (OS) in B-ALL patients. Supplemental Table 9. Clinical characteristics of patients studied in scDNA + protein sequencing experiments. Supplemental Table 10. Clinical characteristics of patients studied in scRNA-seq experiment. Supplemental Table 11. Ingenuity pathway analysis comparing B-lymphoblasts from B-ALL with MyM vs B-ALL without MyM.

Year:

2024

Supplemental Figure 1. WHO/ICC subtypes for the B-ALL cohort. Supplemental Figure 2. Lymphoid clonal hematopoiesis (CH) mutations are less common in adults with ALL. Supplemental Figure 3. Blast percentage in the pre-treatment sample and detected variant allelic frequencies (VAF) of mutations in ALL patients with myeloid mutations. Supplemental Figure 4. Germline testing in the adult ALL cohort. Supplemental Figure 5. Associations of gene mutations and WHO/ICC disease subtypes in B-ALL. Supplemental Figure 6. Overall survival in adults with B-ALL. Supplemental Figure 7. Kaplan-Meier overall survival curves for Ph-negative B-ALL patients stratified based on the presence of TP53 and non-TP53 MyM (A), and treatment with different chemotherapy protocols (B, C, D). LH, low hypodiploidy. Supplemental Figure 8. T-lineage ALL with myeloid mutations (MyM). Supplemental Figure 9. Expression levels of lineage-specific surface markers. Supplemental Figure 10. Single cell DNA and protein sequencing to study the clonal architecture of Tlineage ALL with MyM. Supplemental Figure 11. A, Flow plots showing ETP-lymphoblast, myeloid, and mature lymphocytic compartments of ETP-ALL1, which were sorted for DNA extraction and sequencing. B, Distribution of variant allelic frequencies (VAFs) for myeloid (IDH2, DNMT3A) and NRAS mutations across subpopulations of cells in ETP-ALL1. Supplemental Figure 12. Clonal dynamics of ALL with MyM. Supplemental Figure 13. Two CH mutations (TP53 and DNMT3A) were detectable seven years before the diagnosis of therapy-related ALL22. Supplemental Figure 14. Clonal evolution of B-ALL2. Supplemental Figure 15. Lymphoblasts from B-ALL with MyM are characterized by their resistance to cytotoxic chemotherapy. Supplemental Figure 16. Curves showing viability of primary human B-ALL samples with TP53 mutation (n= 14), MyM (n= 16) and no MyM/TP53 (n= 24), treated with vincristine, doxorubicin, and blinatumomab at escalating doses. Supplemental Figure 17. Flow cytometry plots showing ALL22 (TP53-mutated B-ALL) sample treated with escalating doses of blinatumomab. Supplemental Figure 18. A, CR with MRD negativity rates in Ph-negative B-ALL patients treated with pediatric regimens, stratified based on age, gender, and treatment site. B, CR with MRD negativity rates in Ph-negative B-ALL patients treated with hyper-CVAD, stratified based on age, gender, and treatment site. C, CR with MRD negativity rates in Ph-negative B-ALL patients treated with inotuzumab. Supplemental Figure 19. A, MHC class I and II antigen expression in blasts from B-ALL with MyM vs B-ALL without MyM/TP53. B, Comparison of genes implicated in blinatumomab resistance in B-ALL with vs without MyM/TP53.

Year:

2024

Supplemental Table 1. List of DNA gene mutations tested in diagnostic tumor samples of our ALL cohort. Supplemental Table 2. List of 80 genes with RNA sequencing coverage. Supplemental Table 3. Demographics of 400 adult ALL cases. Supplemental Table 4. List of first-line (initial) therapies in Ph-positive B-ALL, Ph-negative B-ALL, and Tlineage ALL patients. Supplemental Table 5. Baseline gene rearrangements and structural variants of 329 molecularly characterized adult B-ALL patients. Supplemental Table 6. Baseline gene rearrangements and structural variants of 71 molecularly characterized adult T-lineage ALL patients. Supplemental Table 7. List of pathogenic/likely pathogenic germline variants in our ALL cohort. Supplementary Table 8. Multivariable analysis of overall survival (OS) in B-ALL patients. Supplemental Table 9. Clinical characteristics of patients studied in scDNA + protein sequencing experiments. Supplemental Table 10. Clinical characteristics of patients studied in scRNA-seq experiment. Supplemental Table 11. Ingenuity pathway analysis comparing B-lymphoblasts from B-ALL with MyM vs B-ALL without MyM.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (38)

Sharon E. Plon

Professor and Assistant Dean

Baylor College of Medicine

UNITED STATES
View details

Alison Bertuch

Professor

Baylor College of Medicine

UNITED STATES
View details

Sharon Savage

Clinical Director

National Cancer Institute

UNITED STATES
View details

Marlise Luskin

Dana-Farber Cancer Institute

UNITED STATES
View details

Girish Venkataraman

Asst Professor

University of Chicago Pritzker School of Medicine

UNITED STATES
View details

Lisa J. McReynolds

National Institutes of Health

UNITED STATES
View details

Sandeep Gurbuxani

Professor

University of Chicago

UNITED STATES
View details

Rosa Lapalombella

Ohio State University

UNITED STATES
View details

Anand Ashwin Patel

Assistant Professor of Medicine

-

UNITED STATES
View details

Adam Sperling

Assistant Professor

Stanford University

UNITED STATES
View details

Marcin W Wlodarski

PI

St. Jude Children's Research Hospital

UNITED STATES
View details

Luke D. Maese

Huntsman Cancer Institute

UNITED STATES
View details

Vivian Y. Chang

University of California

UNITED STATES
View details

Benjamin Ebert

Dana-Farber Cancer Institute

UNITED STATES
View details

Samuel McBrayer

Assistant Professor

University of Texas Southwestern Department of Pediatrics

UNITED STATES
View details

Jason Farrar

Professor

University of Arkansas for Medical Sciences

UNITED STATES
View details

Peppi Koivunen

Professor

University of Oulu

FINLAND
View details

Soheil Meshinchi

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Lachelle Dawn Weeks

Dana-Farber Cancer Institute

UNITED STATES
View details

Tim Triche

Associate Professor

Van Andel Institute

UNITED STATES
View details

Cihangir Duy

Assistant Professor

Fox Chase Cancer Center

UNITED STATES
View details

Ryan Looper

Associate Professor

University of Utah

UNITED STATES
View details

Kim Erika Nichols

Full Member

St. Jude Children's Research Hospital

UNITED STATES
View details

Gaëlle Bougeard

University of Rouen

FRANCE
View details

Christopher C. Porter

Emory University School of Medicine

UNITED STATES
View details

Ryan A. Chisholm

-

SINGAPORE
View details

Daniel Arber

Professor and Chair

University of Chicago

UNITED STATES
View details

Ulrich Steidl

Albert Einstein College of Medicine

UNITED STATES
View details

Roland Kuiper

Senior Principal Investigator

Princess Máxima Center for Pediatric Oncology

NETHERLANDS
View details

Peng Wang

Associate professor

University of Chicago Medicine

UNITED STATES
View details

Sarah Scollon

Assistant Professsor/Genetic Counselor

Baylor College of Medicine

UNITED STATES
View details

Wendy Stock

Professor of Medicine

University of Chicago

UNITED STATES
View details

Keith Ligon

Chief of Neuropathology/Principal Investigator

Dana-Farber Cancer Institute

UNITED STATES
View details

John Greally

Director, New York Center for Rare Diseases (NYCRD)

Albert Einstein College of Medicine

UNITED STATES
View details

Richard Larson

Professor

University of Chicago

UNITED STATES
View details

Julia Meade

Associate Professor of Pediatrics

West Virginia University

UNITED STATES
View details

Angela Lager

Assistant Professor

University of Chicago

UNITED STATES
View details

Hamish Scott

University of South Australia

AUSTRALIA
View details